INCLINE VILLAGE, Nev., Nov. 12, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that company management will present at the Jefferies 2014 Global Healthcare Conference next week in London. The presentation, which will be webcast, will occur on November 19, 2014 at 8:40 a.m. London time (3:40 a.m. EST).
To access the live and subsequently archived webcast of the presentation, go to the Company's website at http://www.pdl.com and go to "Events and Presentations." Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The archived webcast will be available for at least seven days following the presentation.
About PDL BioPharma, Inc.
PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue. PDL is currently focused on intellectual property asset management, acquiring new income generating assets, and maximizing value for its shareholders.
The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada.
PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has deployed approximately $780 million to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment.
PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
SOURCE PDL BioPharma, Inc.